NCT04516213View on ClinicalTrials.gov

Study to Evaluate the Tolerance and Safety of a Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG)

NACompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2020

Primary Completion Date

June 1, 2021

Study Completion Date

June 1, 2021

Conditions
Enteral Nutrition
Interventions
OTHER

Enteral Formula With (PHGG)

Pediatric subjects will be fed a Peptide-based Enteral Formula With Partially Hydrolyzed Guar Gum (PHGG)

Trial Locations (5)

33021

Children's Center for GI and Nutrition, Hollywood

46202

Riley Children's Hospital, Indianapolis

60637

The University of Chicago Medicine, Chicago

64108

The Children's Mercy Hospital, Kansas City

84113-1125

University of Utah Health Care - Huntsman Cancer Institute (HCI), Salt Lake City

All Listed Sponsors
lead

Société des Produits Nestlé (SPN)

INDUSTRY

NCT04516213 - Study to Evaluate the Tolerance and Safety of a Peptide-based Enteral Formula with Partially Hydrolyzed Guar Gum (PHGG) | Biotech Hunter | Biotech Hunter